Evidence map›Paper›PMID 41332553›Full record

ArticlebioRxiv : the preprint server for biology2025

Epistasis and background dependence in the evolution of Omicron variants of the SARS-CoV-2 Spike protein.

Alief Moulana, Thomas Dupic, Michael M Desai

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Alief MoulanaDepartment of Organismic and Evolutionary Biology, Harvard University; Cambridge, MA, USA.
Thomas DupicDepartment of Organismic and Evolutionary Biology, Harvard University; Cambridge, MA, USA.
Michael M DesaiDepartment of Organismic and Evolutionary Biology, Harvard University; Cambridge, MA, USA.

Funding

Microbial Adaptation and the Statistics of Epistasis and PleiotropyR01GM104239 · NIGMS · HARVARD UNIVERSITY · PI DESAI, MICHAEL M · 2013 to 2025
$4.5M
NIGMS NIH HHS R01 GM104239
6 · The paper itself

Abstract

The rapid and repeated emergence of SARS-CoV-2 variants, particularly within the Omicron lineage, highlights the virus's remarkable ability to adapt under shifting immune pressures. A central molecular battleground in this evolutionary arms race is the spike receptor-binding domain (RBD), which must simultaneously maintain high affinity for the human ACE2 receptor while evading recognition by neutralizing antibodies. In this study, we construct and analyze multiple combinatorial libraries of SARS-CoV-2 RBD variants spanning major branches of Omicron evolution, including BA.1, BA.2, BA.5, XBB, and JN.1. Using high-throughput yeast display and binding assays, we map the effects of thousands of mutations and their combinations on ACE2 binding and antibody evasion. Our results reveal that while many RBD mutations exhibit additive effects, several mutations interact epistatically in a background-dependent manner. In particular, we identify synergistic interactions between BA.1 and BA.5 mutations that enhance antibody evasion, likely facilitating the rise of recombinant variants and convergent evolution. Conversely, some mutations show lineage-restricted compatibility, suggesting potential constraints on future evolutionary trajectories. Our comprehensive genotype-to-phenotype maps uncover both rugged and smooth regions of the viral fitness landscape and underscore the importance of epistasis in shaping SARS-CoV-2 evolution. These findings improve our ability to anticipate future viral variants and provide a framework for understanding how host-pathogen co-evolution unfolds at the molecular level.

Identifiers

PMID41332553
PMCPMC12667959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.